Inspire Trust Co. N.A. boosted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 27.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,000 shares of the company's stock after purchasing an additional 6,000 shares during the period. Inspire Trust Co. N.A.'s holdings in Novo Nordisk A/S were worth $1,944,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL grew its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Transce3nd LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. North Capital Inc. bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $27,000. Finally, Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on NVO. Hsbc Global Res cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Finally, BNP Paribas raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus price target of $83.75.
Read Our Latest Research Report on Novo Nordisk A/S
Novo Nordisk A/S Stock Up 2.2%
NVO stock opened at $50.90 on Thursday. The firm has a market cap of $227.27 billion, a PE ratio of 13.98, a P/E/G ratio of 1.71 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm's fifty day moving average is $65.84 and its 200 day moving average is $70.91. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $139.74.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.
Novo Nordisk A/S Cuts Dividend
The company also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 45.05%.
Novo Nordisk A/S Profile
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.